192 related articles for article (PubMed ID: 34954472)
41. Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
Liu Q; Tan C; Yi L; Wan X; Peng L; Li J; Luo X; Zeng X
PLoS One; 2021; 16(11):e0258605. PubMed ID: 34780478
[TBL] [Abstract][Full Text] [Related]
42. Treatment patterns and outcomes among patients with small-cell lung cancer (SCLC) in Europe: a retrospective cohort study.
Blackhall F; Girard N; Livartowski A; McDonald L; Roset M; Lara N; Juarez García A
BMJ Open; 2023 Feb; 13(2):e052556. PubMed ID: 36746549
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of carboplatin and etoposide in older extensive-stage small-cell lung cancer patients with a poor performance status.
Mamesaya N; Kodama H; Iida Y; Kobayashi H; Ko R; Wakuda K; Ono A; Kenmotsu H; Naito T; Murakami H; Shimizu T; Gon Y; Takahashi T
Thorac Cancer; 2023 Mar; 14(9):805-814. PubMed ID: 36700290
[TBL] [Abstract][Full Text] [Related]
44. Guideline for the Initial Management of Small Cell Lung Cancer (Limited and Extensive Stage) and the Role of Thoracic Radiotherapy and First-line Chemotherapy.
Sun A; Durocher-Allen LD; Ellis PM; Ung YC; Goffin JR; Ramchandar K; Darling G
Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):658-666. PubMed ID: 30007803
[TBL] [Abstract][Full Text] [Related]
45. Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer.
Rittberg R; Leung B; Al-Hashami Z; Ho C
Front Oncol; 2022; 12():1002385. PubMed ID: 36185266
[TBL] [Abstract][Full Text] [Related]
46. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
Socinski MA; Smit EF; Lorigan P; Konduri K; Reck M; Szczesna A; Blakely J; Serwatowski P; Karaseva NA; Ciuleanu T; Jassem J; Dediu M; Hong S; Visseren-Grul C; Hanauske AR; Obasaju CK; Guba SC; Thatcher N
J Clin Oncol; 2009 Oct; 27(28):4787-92. PubMed ID: 19720897
[TBL] [Abstract][Full Text] [Related]
47. A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial.
Morabito A; Daniele G; Costanzo R; Favaretto AG; Filipazzi V; Rossi A; Gebbia V; Castiglione F; Cavanna L; Maiello E; Sandomenico C; Bonanno L; Piazza E; Maione P; Piccirillo MC; Di Maio M; Rocco G; Gallo C; Perrone F; Gridelli C
Lung Cancer; 2017 Jun; 108():15-21. PubMed ID: 28625627
[TBL] [Abstract][Full Text] [Related]
48. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
Rudin CM; Awad MM; Navarro A; Gottfried M; Peters S; Csőszi T; Cheema PK; Rodriguez-Abreu D; Wollner M; Yang JC; Mazieres J; Orlandi FJ; Luft A; Gümüş M; Kato T; Kalemkerian GP; Luo Y; Ebiana V; Pietanza MC; Kim HR;
J Clin Oncol; 2020 Jul; 38(21):2369-2379. PubMed ID: 32468956
[TBL] [Abstract][Full Text] [Related]
49. A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer.
Salgia R; Stille JR; Weaver RW; McCleod M; Hamid O; Polzer J; Roberson S; Flynt A; Spigel DR
Lung Cancer; 2017 Mar; 105():7-13. PubMed ID: 28236984
[TBL] [Abstract][Full Text] [Related]
50. Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium.
Spigel DR; Hainsworth JD; Shipley DL; Mekhail TM; Zubkus JD; Waterhouse DM; Daniel DB; Burris HA; Greco FA
Lung Cancer; 2018 Mar; 117():38-43. PubMed ID: 29496254
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
Igawa S; Shirasawa M; Fukui T; Nishinarita N; Sone H; Ozawa T; Sugita K; Okuma Y; Kurahayashi S; Ono T; Sugimoto A; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
Oncology; 2018; 94(4):207-214. PubMed ID: 29393275
[TBL] [Abstract][Full Text] [Related]
52. Outcome of treatment in patients with small cell lung cancer in poor performance status.
Bahij R; Jeppesen SS; Olsen KE; Halekoh U; Holmskov K; Hansen O
Acta Oncol; 2019 Nov; 58(11):1612-1617. PubMed ID: 31282251
[No Abstract] [Full Text] [Related]
53. [Second-line chemotherapy and its survival analysis of 181 patients with extensive-stage small cell lung cancer in a single institute].
Ma M; Wang M; Xu Y; Hu K; Liu H; Li L; Zhong W; Zhang L; Zhao J; Wang H
Zhongguo Fei Ai Za Zhi; 2013 Nov; 16(11):572-8. PubMed ID: 24229622
[TBL] [Abstract][Full Text] [Related]
54. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial.
Spigel DR; Townley PM; Waterhouse DM; Fang L; Adiguzel I; Huang JE; Karlin DA; Faoro L; Scappaticci FA; Socinski MA
J Clin Oncol; 2011 Jun; 29(16):2215-22. PubMed ID: 21502556
[TBL] [Abstract][Full Text] [Related]
55. Investigation of poor predictive factors in extensive stage small cell lung cancer under etoposide-platinum-atezolizumab treatment.
Lim JU; Kang HS; Shin AY; Yeo CD; Kim SK; Kim JW; Kim SJ; Lee SH
Thorac Cancer; 2022 Dec; 13(23):3384-3392. PubMed ID: 36274214
[TBL] [Abstract][Full Text] [Related]
56. Thoracic radiotherapy may improve the outcome of extensive stage small cell lung carcinoma patients treated with first-line immunotherapy plus chemotherapy.
Wu JJ; Huang JW; Hsu KH; Huang YH; Chen KC; Tseng JS; Yang TY; Chang GC
Anticancer Drugs; 2022 Nov; 33(10):e842-e849. PubMed ID: 36206101
[TBL] [Abstract][Full Text] [Related]
57. Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer.
Imai H; Mori K; Watase N; Kazama T; Fujimoto S; Kaira K; Yamada M; Minato K
Thorac Cancer; 2016 Nov; 7(6):655-662. PubMed ID: 27755823
[TBL] [Abstract][Full Text] [Related]
58. [Correlations between genetic variations of glutathione synthetase gene and the response to platinum-based chemotherapy and prognosis of small cell lung cancer patients].
Feng T; Li HM; Yuan P; Yu DK; Ma F; Tan WW; Du ZL; Yang J; Huang Y; Lin DX; Xu BH; Tan W
Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):115-120. PubMed ID: 28219206
[No Abstract] [Full Text] [Related]
59. Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report.
Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Lange W; Mertelsmann R
Ann Oncol; 1999 May; 10(5):561-7. PubMed ID: 10416006
[TBL] [Abstract][Full Text] [Related]
60. [First-line chemotherapy and its survival analysis of 394 patients with extensive-stage small cell lung cancer in a single institute].
Ma M; Wang M; Xu Y; Hu K; Liu H; Li L; Zhong W; Zhang L; Zhao J; Wang H
Zhongguo Fei Ai Za Zhi; 2014 Jan; 17(1):8-14. PubMed ID: 24398308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
